Claritev Corp (CTEV) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Claritev Corp (formerly MultiPlan Corporation) is a leading provider of data-driven cost management solutions for the healthcare industry. The company changed its name and ticker symbol to "CTEV" in February 2025. The financial statements reflect a one-for-forty reverse stock split effective September 20, 2024.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $245.96M | $230.50M | $718.86M | $698.48M |
| Operating Income (Loss) | $10.07M | ($338.21M) | $36.39M | ($1,348.57M) |
| Net Loss | ($69.75M) | ($391.45M) | ($203.71M) | ($1,507.87M) |
| Adjusted EBITDA | $155.13M | $141.65M | $451.23M | $435.11M |
| Cash & Equivalents | $39.15M | $16.85M | Total Cash (incl. restricted): $50.65M | |
| Total Debt (Gross) | $4.60B | $4.57B | Includes $70M revolver draw | |
| Operating Cash Flow (9M) | $51.04M | $141.03M (Prior Year) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 6.7% year-over-year, driven by Network-Based Services (+14.6%) and Analytics-Based Services (+4.2%).
- Profitability Improvement: The company returned to operating profitability ($10.1M) in Q3 2025, compared to a significant operating loss in Q3 2024. This improvement is largely due to the absence of goodwill impairment charges that totaled $361.6M in Q3 2024.
- Expense Increases: General and Administrative (G&A) expenses rose 64.1% in Q3 2025, primarily due to $13.9M in transformation costs ("Vision 2030"), increased personnel costs, and higher stock-based compensation.
- Debt Restructuring: In January 2025, the company completed a major refinancing transaction, exchanging existing notes and term loans for new "First-Out" and "Second-Out" term loans and notes, and establishing a new $350M revolving credit facility.
Guidance, Outlook, and Risks
- Outlook: Management does not provide specific numerical guidance in this filing but highlights a focus on the "Vision 2030" transformation program and international expansion into the Middle East and North Africa (MENA) region via a partnership with Claims Care.
- Liquidity: As of September 30, 2025, the company had $273.6M of availability under its revolving credit facility. Management believes current liquidity sources are sufficient for the next 12 months.
- Risks:
- Legal Proceedings: The company is a defendant in multidistrict antitrust litigation alleging conspiracy with payors to suppress out-of-network reimbursements. Discovery is ongoing.
- ERP Implementation: Risks associated with the implementation of a new SAP ERP system, including potential disruptions to operations and internal controls.
- Customer Concentration: Three clients accounted for 28%, 11%, and 10% of revenue in the first nine months of 2025.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to maintain the consolidated first-out, first-lien debt to consolidated EBITDA ratio (not to exceed 2.50:1.00) if revolver utilization exceeds 40%.
- Transformation Costs: Monitor the trajectory of "Vision 2030" transformation costs, which significantly impacted G&A expenses in 2025.
- Antitrust Litigation: Track developments in the multidistrict antitrust litigation, as a negative outcome could materially impact operations.
- Revenue Mix: Analyze the sustainability of the growth in Network-Based Services versus the slight decline in Analytics-Based Services over the nine-month period.
- Interest Expense: Review the impact of the new debt structure on interest expense, which increased 23.8% in Q3 2025 due to non-cash interest on new notes.